

86CANCER
Compiled Financial Information
Year Ended September 30, 2023

86CANCER
Index to Compiled Financial Information
Year Ended September 30, 2023

	Page
COMPILATION ENGAGEMENT REPORT	1
COMPILED FINANCIAL INFORMATION	
Statement of Financial Position	2
Statement of Revenues and Expenditures	3
Statement of Changes in Net Debt	4
Notes to Compiled Financial Information	5



COMPILATION ENGAGEMENT REPORT

To the Management of 86Cancer

On the basis of information provided by management, I have compiled the statement of financial position of 86Cancer as at September 30, 2023, and the statements of revenues and expenditures and changes in net debt for the year then ended, and Note 1, which describes the basis of accounting applied in the preparation of the compiled financial information ("financial information").

Management is responsible for the accompanying financial information, including the accuracy and completeness of the underlying information used to compile it and the selection of the basis of accounting.

I performed this engagement in accordance with Canadian Standard on Related Services (CSRS) 4200, *Compilation Engagements*, which requires me to comply with relevant ethical requirements. My responsibility is to assist management in the preparation of the financial information.

I did not perform an audit engagement or a review engagement, nor was I required to perform procedures to verify the accuracy or completeness of the information provided by management. Accordingly, I do not express an audit opinion or a review conclusion, or provide any form of assurance on the financial information.

Readers are cautioned that the financial information may not be appropriate for their purposes.

Cold Lake, Alberta
June 7, 2024

Benjamin Dyck Professional Corporation
Chartered Professional Accountant

86CANCER
Statement of Financial Position
September 30, 2023

	2023	2022
ASSETS		
CURRENT		
Cash	\$ 638	\$ 533
LIABILITIES AND NET ASSETS		
CURRENT		
Accounts payable	\$ 499	\$ 500
Short term debt	1,777	1,409
Due to directors	3,333	2,685
	5,609	4,594
NET ASSETS	(4,971)	(4,061)
	\$ 638	\$ 533

ON BEHALF OF THE BOARD

Director

Director

See notes to financial information

86CANCER
Statement of Revenues and Expenditures
Year Ended September 30, 2023

	2023	2022
REVENUES		
Product	\$ 3,851	\$ 5,465
Shipping	-	81
Donations	799	1,711
Event income	7,728	-
	<u>12,378</u>	<u>7,257</u>
COST OF SALES		
Purchases	1,589	399
Merchant fees	466	460
	<u>2,055</u>	<u>859</u>
GROSS PROFIT (83.40%; 2022 - 88.16%)	<u>10,323</u>	<u>6,398</u>
EXPENSES		
Advertising and promotion	547	192
Business taxes, licences and memberships	506	662
Consulting fees	-	868
Donations	9,200	5,853
Interest and bank charges	372	130
Professional fees	608	514
	<u>11,233</u>	<u>8,219</u>
DEFICIENCY OF REVENUES OVER EXPENSES	<u>\$ (910)</u>	<u>\$ (1,821)</u>

86CANCER
Statement of Changes in Net Debt
Year Ended September 30, 2023

	2023	2022
NET DEBT - BEGINNING OF YEAR	\$ (4,061)	\$ (2,240)
DEFICIENCY OF REVENUES OVER EXPENSES	<u>(910)</u>	<u>(1,821)</u>
NET DEBT - END OF YEAR	<u>\$ (4,971)</u>	<u>\$ (4,061)</u>

See notes to financial information

86CANCER
Notes to Compiled Financial Information
Year Ended September 30, 2023

1. BASIS OF ACCOUNTING

The basis of accounting applied in the preparation of the statement of financial position of 86Cancer as at September 30, 2023, and the statements of revenues and expenditures and changes in net debt for the year then ended is the historical cost basis and reflects cash transactions with the addition of:

- Accounts payable and accrued liabilities.
-